| Code | CSB-RA005157MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to CM-24, targeting CEACAM1 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1), a transmembrane glycoprotein that functions as an immune checkpoint regulator. CEACAM1 is expressed on various immune cells, epithelial cells, and endothelial cells, where it modulates T cell activation, natural killer cell function, and inflammatory responses. The protein plays a critical role in maintaining immune homeostasis but is frequently exploited by tumors as an immune evasion mechanism. Aberrant CEACAM1 expression has been documented in multiple malignancies, including melanoma, lung cancer, colorectal cancer, and pancreatic cancer, where it correlates with disease progression and poor prognosis.
CM-24, the reference antibody, is a clinical-stage immunotherapeutic agent that blocks CEACAM1-mediated immune suppression, thereby enhancing anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating CEACAM1 biology, tumor-immune interactions, and immune checkpoint pathways. It supports studies exploring combination immunotherapy strategies and the mechanistic understanding of CEACAM1's role in cancer immune evasion and autoimmune disorders.
There are currently no reviews for this product.